BioXcel Therapeutics to Host Second Quarter 2018 Financial Results and Business Update

BioXcel Therapeutics to Host Second Quarter 2018 Financial Results and Business Update

Conference call scheduled on August 8, 2018 at 4:30 PM ET

NEW HAVEN, Conn., Aug. 02, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology, today announced that it will release its financial results for the second quarter ended June 30, 2018 on Wednesday, August 8, 2018. The Company will hold a conference call at 4:30 PM Eastern Time on Wednesday, August 8, 2018 to discuss the financial results and provide a business update.

CONFERENCE CALL & WEBCAST-
Wednesday, August 8, 2018, 4:30 p.m. Eastern Time
Domestic:800-347-6311
International:323-794-2094
Conference ID:8850726
Webcast:http://public.viavid.com/index.php?id=130885 
Replay – Available through September 8, 2018
Domestic:844-512-2921
International:412-317-6671
Conference ID:8850726
  

About BioXcel Therapeutics, Inc. (BTI): 
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology. BTI’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI’s two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. For more information, please visit www.bioxceltherapeutics.com.

Contact Information:
The Ruth Group for BTI:
Lee Roth / Janhavi Mohite
646-536-7012 / 7026
[email protected] / [email protected]